High-risk liver transplant candidates: An ethical proposal on where to draw the line

Liver Transplantation

Volumn 21, Issue 5, 2015, Pages 607-611

  Schiano, Thomas D ^a,b   Bourgoise, Tyler ^a   Rhodes, Rosamond ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; ASCITES; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMORBIDITY; DECISION MAKING; DISEASE FREE SURVIVAL; DISEASE REGISTRY; HEMODIALYSIS; HIGH RISK PATIENT; HOSPITAL POLICY; HUMAN; JAUNDICE; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; MANTLE CELL LYMPHOMA; MEDICAL ETHICS; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL PREDICTION; COMPLICATION; END STAGE LIVER DISEASE; ETHICS; GRAFT SURVIVAL; HEPATITIS B; HOSPITAL ADMISSION; LEGISLATION AND JURISPRUDENCE; PATIENT SELECTION; PROCEDURES; RISK; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

COMORBIDITY; END STAGE LIVER DISEASE; GRAFT SURVIVAL; HEPATITIS B; HUMANS; LIVER TRANSPLANTATION; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PATIENT SELECTION; RISK; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; UNITED STATES; WAITING LISTS;

EID: 84928584302     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24087     Document Type: Article

References (12)

1. Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 2004; 39: 230-238.
2. Lee KW, Yi NJ, Suh KS,. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience. Transplantation 2014; 97 (suppl 8): S20-S23.
3. Aristotle,. The Nicomachean Ethics of Aristotle. Ross WD, trans. London, England: Oxford University Press; 1971.
4. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, Merion RM,. Survival benefit-based decreased-donor liver allocation. Am J Transplant 2009; 9 (pt 2): 970-981.
5. Freeman RB, Jamieson N, Schaubel DE, Porte RJ, Villamil FG,. Who should get a liver graft? J Hepatol 2009; 50: 664-673.
6. Merion RM, Sharma P, Mathur AK, Schaubel DE,. Evidence-based development of liver allocation: a review. Transpl Int 2011; 24: 965-972.
7. Keller EJ, Kwo PY, Helft PR,. Ethical considerations surrounding survival benefit-based liver allocation. Liver Transpl 2014; 20: 140-146.
8. Volk ML, Biggins SW, Huang MA, Argo CK, Fontana RJ, Anspach RR,. Decision making in liver transplant selection committees: a multicenter study. Ann Intern Med 2011; 155: 503-508.
9. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
10. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-1188.
11. Secunda K, Gordon EJ, Sohn MW, Shinkunas LA, Kaldjian LC, Voigt MD, Levitsky J,. National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transpl 2013; 19: 395-403.
12. US Department of Health and Human Services. Scientific Registry of Transplant Recipients. http://srtr.transplant.hrsa.gov. Accessed February 19, 2015.